

# Metastatic Uveal Melanoma (MUM) - Market Insights, Epidemiology, and Market Forecast 2028

<https://marketpublishers.com/r/MB05C63D31BEN.html>

Date: August 2019

Pages: 120

Price: US\$ 6,250.00 (Single User License)

ID: MB05C63D31BEN

## Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's "Metastatic Uveal Melanoma (MUM) - Market Insights, Epidemiology and Market Forecast – 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted Metastatic Uveal Melanoma (MUM) epidemiology. It highlights the existing treatment patterns, potential upcoming Metastatic Uveal Melanoma (MUM) drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028.

### Markets Covered

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2017-2028

### Metastatic Uveal Melanoma (MUM) Understanding and Treatment Algorithm

The Metastatic Uveal Melanoma (MUM) market report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details

about treatment algorithms and treatment guidelines for Metastatic Uveal Melanoma (MUM) in the US, Europe, and Japan are also provided in the report.

### Metastatic Uveal Melanoma (MUM) Epidemiology

This section provide the insights about historical and current Metastatic Uveal Melanoma (MUM) patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

### Metastatic Uveal Melanoma (MUM) Product Profiles & Analysis

This part of the report encloses the detailed analysis of Metastatic Uveal Melanoma (MUM) marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

### Metastatic Uveal Melanoma (MUM) Market Outlook

The Metastatic Uveal Melanoma (MUM) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight. **Metastatic Uveal Melanoma (MUM) Market Share by Therapies**

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and

the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

## Metastatic Uveal Melanoma (MUM) Report Insights

Metastatic Uveal Melanoma (MUM) Patient Population

Metastatic Uveal Melanoma (MUM) Therapeutic Approaches

Metastatic Uveal Melanoma (MUM) Pipeline Analysis

Metastatic Uveal Melanoma (MUM) Market Size and Trends

Metastatic Uveal Melanoma (MUM) Market Opportunities

Impact of upcoming Therapies in Metastatic Uveal Melanoma (MUM)

## Metastatic Uveal Melanoma (MUM) Report Key Strengths

Metastatic Uveal Melanoma (MUM) 10 Year Forecast

Metastatic Uveal Melanoma (MUM) 7MM Coverage

Metastatic Uveal Melanoma (MUM) Epidemiology Segmentation

Metastatic Uveal Melanoma (MUM) Drugs Uptake

Highly Analyzed Metastatic Uveal Melanoma (MUM) Market

Key Cross Competition

## Metastatic Uveal Melanoma (MUM) Report Assessment

Current Treatment Practices in Metastatic Uveal Melanoma (MUM)

Metastatic Uveal Melanoma (MUM) Unmet Needs

Detailed Metastatic Uveal Melanoma (MUM) Pipeline Product Profiles

Metastatic Uveal Melanoma (MUM) Market Attractiveness

Metastatic Uveal Melanoma (MUM) Market Drivers and Barriers

## Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Metastatic Uveal Melanoma (MUM) market

Organize sales and marketing efforts by identifying the best opportunities for Metastatic Uveal Melanoma (MUM) market

To understand the future market competition in the Metastatic Uveal Melanoma (MUM) market.

## Contents

### **1. REPORT INTRODUCTION**

### **2. METASTATIC UVEAL MELANOMA (MUM) MARKET OVERVIEW AT A GLANCE**

2.1. Market Share Distribution of Metastatic Uveal Melanoma (MUM) in 2017

2.2. Market Share Distribution of Metastatic Uveal Melanoma (MUM) in 2028

### **3. DISEASE BACKGROUND AND OVERVIEW: METASTATIC UVEAL MELANOMA (MUM)**

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

### **4. EPIDEMIOLOGY AND PATIENT POPULATION**

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Metastatic Uveal Melanoma (MUM) in 7MM

4.3. Total Prevalent Patient Population of Metastatic Uveal Melanoma (MUM) in 7MM – By Countries

### **5. EPIDEMIOLOGY OF METASTATIC UVEAL MELANOMA (MUM) BY COUNTRIES**

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM)

5.1.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) \*Indication Specific

5.1.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) \*Indication Specific

5.1.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM)

5.1.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM)

## 5.2. EU5

### 5.3. Assumptions and Rationale

### 5.4. Germany

#### 5.4.1. Assumptions and Rationale

#### 5.4.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM)

#### 5.4.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) \*

#### 5.4.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) \*

#### 5.4.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM)

#### 5.4.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM)

### 5.5. France

#### 5.5.1. Assumptions and Rationale

#### 5.5.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM)

#### 5.5.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) \*

#### 5.5.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) \*

#### 5.5.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM)

#### 5.5.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM)

### 5.6. Italy

#### 5.6.1. Assumptions and Rationale

#### 5.6.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM)

#### 5.6.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) \*

#### 5.6.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) \*

#### 5.6.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM)

#### 5.6.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM)

### 5.7. Spain

#### 5.7.1. Assumptions and Rationale

#### 5.7.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM)

#### 5.7.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) \*

#### 5.7.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) \*

#### 5.7.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM)

#### 5.7.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM)

### 5.8. United Kingdom

#### 5.8.1. Assumptions and Rationale

#### 5.8.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM)

#### 5.8.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) \*

#### 5.8.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) \*

#### 5.8.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM)

#### 5.8.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM)

### 5.9. Japan

#### 5.9.1. Assumptions and Rationale

- 5.9.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM)
- 5.9.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) \*
- 5.9.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) \*
- 5.9.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM)
- 5.9.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM)

## **6. CURRENT TREATMENT & MEDICAL PRACTICES**

- 6.1. Treatment Algorithm
- 6.2. Treatment Guidelines

## **7. UNMET NEEDS OF THE METASTATIC UVEAL MELANOMA (MUM)**

## **8. MARKETED THERAPIES**

- 8.1. Drug A: Company
  - 8.1.1. Drug Description
  - 8.1.2. Mechanism of Action
  - 8.1.3. Regulatory Milestones
  - 8.1.4. Advantages & Disadvantages
  - 8.1.5. Product Profile
- 8.2. Drug B: Company
  - 8.2.1. Drug Description
  - 8.2.2. Mechanism of Action
  - 8.2.3. Regulatory Milestones
  - 8.2.4. Advantages & Disadvantages
  - 8.2.5. Product Profile

## **9. PIPELINE THERAPIES – AT A GLANCE**

## **10. KEY CROSS COMPETITION**

## **11. EMERGING THERAPIES FOR METASTATIC UVEAL MELANOMA (MUM)**

- 11.1. Drug C: Company
  - 11.1.1. Drug Description
  - 11.1.2. Clinical Trials Details
  - 11.1.3. Safety and Efficacy Profile
  - 11.1.4. Advantages & Disadvantages

- 11.1.5. Pipeline Development Activities
- 11.1.6. Product Profile
- 11.2. Drug D: Company
  - 11.2.1. Drug Description
  - 11.2.2. Clinical Trials Details
  - 11.2.3. Safety and Efficacy Profile
  - 11.2.4. Advantages & Disadvantages
  - 11.2.5. Pipeline Development Activities
  - 11.2.6. Product Profile

## **12. METASTATIC UVEAL MELANOMA (MUM) : 7MM MARKET ANALYSIS**

- 12.1. 7MM Market Size of Metastatic Uveal Melanoma (MUM)
- 12.2. 7MM Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM)
- 12.3. 7MM Market Sales of Metastatic Uveal Melanoma (MUM) by Products

## **13. METASTATIC UVEAL MELANOMA (MUM) : COUNTRY-WISE MARKET ANALYSIS**

- 13.1. United States
  - 13.1.1. Market Size of Metastatic Uveal Melanoma (MUM) in United States
  - 13.1.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in United States
  - 13.1.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in United States
  - 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2. EU-5
  - 13.2.1. Germany
    - 13.2.1.1. Market Size of Metastatic Uveal Melanoma (MUM) in Germany
    - 13.2.1.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in Germany
    - 13.2.1.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in Germany
    - 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  - 13.2.2. France
    - 13.2.2.1. Market Size of Metastatic Uveal Melanoma (MUM) in France
    - 13.2.2.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in France
    - 13.2.2.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in France



13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.3. Italy

13.2.3.1. Market Size of Metastatic Uveal Melanoma (MUM) in Italy

13.2.3.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in Italy

13.2.3.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in Italy

13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.4. Spain

13.2.4.1. Market Size of Metastatic Uveal Melanoma (MUM) in Spain

13.2.4.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in Spain

13.2.4.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in Spain

13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.5. United Kingdom

13.2.5.1. Market Size of Metastatic Uveal Melanoma (MUM) in United Kingdom

13.2.5.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in United Kingdom

13.2.5.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in United Kingdom

13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

13.3. Japan

13.3.1. Market Size of Metastatic Uveal Melanoma (MUM) in Japan

13.3.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in Japan

13.3.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in Japan

13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

## **14. MARKET DRIVERS**

## **15. MARKET BARRIERS**

## **16. APPENDIX**

## **17. REPORT METHODOLOGY**

17.1. Sources

## **18. DELVEINSIGHT CAPABILITIES**

## 19. DISCLAIMER

## 20. ABOUT DELVEINSIGHT

## List Of Tables

### LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in 7MM

Table 2: Total Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028)

Table 4: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028)

Table 5: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028)

Table 6: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028)

Table 7: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028)

Table 10: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028)

Table 11: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028)

Table 12: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028)

Table 14: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028)

Table 15: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028)

Table 16: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028)

Table 17: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028)

Table 18: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Italy

(2017-2028)

Table 19: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Italy  
(2017-2028)

Table 20: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Italy  
(2017-2028)

Table 21: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Italy  
(2017-2028)

Table 22: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Italy  
(2017-2028)

Table 23: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Spain  
(2017-2028)

Table 24: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Spain  
(2017-2028)

Table 25: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Spain  
(2017-2028)

Table 26: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Spain  
(2017-2028)

Table 27: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Spain  
(2017-2028)

Table 28: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in UK  
(2017-2028)

Table 29: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in UK  
(2017-2028)

Table 30: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in UK  
(2017-2028)

Table 31: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in UK  
(2017-2028)

Table 32: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Japan  
(2017-2028)

Table 34: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Japan  
(2017-2028)

Table 35: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Japan  
(2017-2028)

Table 36: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Japan  
(2017-2028)

Table 37: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Japan  
(2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41: 7MM- Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Table 42: 7MM- Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 43: 7MM- Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Table 45: United States-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Table 48: Germany-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Table 51: France-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Table 54: Italy-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Table 57: Spain-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 59: UK-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM

(2017-2028)

Table 60:UK-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Table 63: Japan-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

## List Of Figures

### LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028)

Figure 6: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028)

Figure 7: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028)

Figure 12: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028)

Figure 15: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028)

Figure 16: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028)

Figure 17: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Italy

(2017-2028)

Figure 19: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028)

Figure 22: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028)

Figure 27: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028)

Figure 31: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028)

Figure 32: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028)

Figure 37: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028)



Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Figure 42:7MM- Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Figure 45: United States-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Figure 48: Germany-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Figure 51: France-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Figure 54: Italy-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028)

Figure 57: Spain-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM  
(2017-2028)

Figure 60:UK-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD  
MM (2017-2028)

Figure 61:UK-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD  
MM (2017-2028)

Figure 62: Japan-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM  
(2017-2028)

Figure 63: Japan-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in  
USD MM (2017-2028)

Figure 64: Japan-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in  
USD MM (2017-2028)

## I would like to order

Product name: Metastatic Uveal Melanoma (MUM) - Market Insights, Epidemiology, and Market Forecast 2028

Product link: <https://marketpublishers.com/r/MB05C63D31BEN.html>

Price: US\$ 6,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MB05C63D31BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

